Good morning, everyone. My name is Pedro J. Beltran, President and Chief Executive Officer of BridgeBio Oncology Therapeutics. I am here to record the minutes. It is a pleasure to welcome our shareholders to the annual meeting of the corporation. This meeting is being held in accordance with the corporation's bylaws and Delaware law. We will take care of the formal business at hand, which is described in our notice and proxy statement, a copy of which was mailed on or about April 28th, 2026, to all of our stockholders of record at the close of business on April 20th, 2026. All discussion will be limited to the official business at hand. Before proceeding to the formal business, I would like to recognize the directors of the corporation who are with us today. Thank you. I would also like to welcome the members of our executive team and representatives from Deloitte & Touche LLP, the corporation's audit firm, and representatives from Goodwin Procter, our outside counsel. Thank you. Let's proceed to the formal business of the meeting, notice of which was sent to all shareholders of record as of close of business on April 20th, 2026. Shareholders of record of that date are entitled to vote at this meeting. Rules of conduct for the meeting are available in the Meeting Materials section in the lower right-hand corner of the screen. Please note that only stockholders who have logged in using their 16-digit control number will be able to vote and ask questions at the meeting. If you have any questions, I would encourage you to please submit them now so that they will be in the queue to be answered. If any stockholder wishes to address the chairman during the formal parts of this meeting, please do so submitting your questions in writing to the virtual meeting platform via the Ask a Question box in the lower left-hand corner of the screen. The Board of Directors has appointed [John F. Holowach] to act as Inspector of Election for this annual meeting, and he will be tabulating the results of the voting. The Inspector of Election has signed the oath of his office, which will be filed with the minutes of this meeting. [John F. Holowach], do we have a quorum present? Mr. President, of the 80,112,725 shares of common stock entitled to vote at the meeting, 34,539,315 shares are represented either in person or by proxy, therefore, a quorum is present. I declare that a quorum is present. We may now proceed to transact the business for which this meeting has been called. Let me briefly describe the voting procedures. If you have previously turned in your proxy, and you do not intend to change your vote, it is not necessary that you complete another proxy or ballot. Your vote will be counted. If you are eligible to vote and have not submitted your proxy, or if you want to change your vote, you may do so by clicking the Vote Here button on the virtual meeting platform. In order to allow stockholders to vote through the virtual meeting platform at any time during this meeting, I now declare the polls open for voting. It is now 1:04 P.M. on June 16th, 2026. Our first item of business is the election of directors. At this meeting, we will be voting two nominees for Class I directors to serve for a term of three years. All as set forth in the proxy statement. In accordance with the bylaws, your directors have nominated Frank McCormick and Peter Lebowitz to be elected to serve as Class I directors. The corporation's bylaws require that a stockholder provide advance notice to the corporation of a stockholder's intent to nominate persons as directors. No such notice was received. Accordingly, I declare the nominations for directors closed. The board of directors unanimously recommends that stockholders vote in favor of this proposal. Have we received any questions concerning this proposal? No questions have been received concerning this proposal. The second item of business is the ratification of the appointment of Deloitte & Touche as the corporation's independent registered public accounting firm for the fiscal year ending December 31st, 2026. The audit committee of the board of directors, which is comprised entirely of independent directors, appointed Deloitte & Touche as the corporation's independent registered public accounting firm to audit the corporation's financial statements for the fiscal year ending December 31st, 2026. The board of directors approved the selection of Deloitte & Touche LLP, and has asked the stockholders to ratify the selection. Stockholder certification is not required by the corporation bylaws. The board of directors is submitting this to the stockholders for ratification as a matter of good corporate governance. If the stockholders do not approve the selection of Deloitte & Touche as the corporation's independent registered public accounting firm, the board of directors and the audit committee will reconsider the appointment. Have we received any questions concerning the proposal? No questions have been received concerning the proposal. It is now 1:07 P.M. on June 16th, 2026, and the polls for each matter to be voted on at this meeting are now closed. No additional ballots, proxies, or votes, and no changes or revocations will be accepted. Inspector of Election, please report on the results of the voting. With regard to proposal one, a plurality of the shares present or represented and entitled to vote has been voted in favor of the election of the persons nominated. With regard to proposal two, a majority of the shares present or represented and entitled to vote have been voted in favor of the ratification of Deloitte & Touche LLP as the corporation's independent registered accounting firm for the fiscal year ending December 31st, 2026. Thank you, John. I declare that all of the proposals presented at the meeting have been ratified or approved by the stockholders. The final results of the voting, including any ballots and proxies recorded during this meeting, will be set forth in the report of the Inspector of Election and will be included in the minutes of the meeting. The final results will also be included in our reports filed with the SEC. There being no other matters for consideration at this meeting, I hereby adjourn this meeting. The conference is now concluded. Thank you for attending today's presentation. You may now disconnect.